Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia.
Gene. 2020 Aug 20;752:144792. doi: 10.1016/j.gene.2020.144792. Epub 2020 May 20.
The morbidity of SARS-CoV-2 (COVID-19) is reaching 3 Million landmark causing and a serious public health concern globally and it is enigmatic how several antiviral and antibody treatments were not effective in the different period across the globe. With the drastic increasing number of positive cases around the world WHO raised the importance in the assessment of the risk of spread and understanding genetic modifications that could have occurred in the SARS-CoV-2. Using all available deep sequencing data of complete genome from all over the world (NCBI repository), we identified several hundreds of point mutations or SNPs in SARS-CoV-2 all across the genome. This could be the cause for the constant change and differed virulence with an increase in mortality and morbidity. Among the 12 different countries (one sequence from each country) with complete genome sequencing data, we noted the 47 key point mutations or SNPs located along the entire genome that might have impact in the virulence and response to different antivirals against SARS-CoV-2. In this regard, key viral proteins of spike glycoprotein, Nsp1, RdRp and the ORF8 region got heavily mutated within these 3 months via person-to-person passage. We also discuss what could be the possible cause of this rapid mutation in the SARS-CoV-2.
SARS-CoV-2（COVID-19）的发病率已达到 300 万例，成为全球严重的公共卫生关注问题，令人费解的是，在全球不同时期，几种抗病毒和抗体治疗方法为何都无效。随着世界各地阳性病例数量的急剧增加，世界卫生组织（WHO）提高了评估传播风险以及了解 SARS-CoV-2 可能发生的遗传变异的重要性。利用来自全球（NCBI 存储库）的所有可用的 SARS-CoV-2 全基因组深度测序数据，我们在整个基因组中鉴定出了数百个点突变或单核苷酸多态性（SNP）。这可能是导致病毒不断变异和毒力不同的原因，从而导致死亡率和发病率增加。在具有全基因组测序数据的 12 个不同国家（每个国家一个序列）中，我们注意到了位于整个基因组上的 47 个关键突变或 SNP，它们可能对 SARS-CoV-2 的毒力和对不同抗病毒药物的反应产生影响。在这方面，刺突糖蛋白、Nsp1、RdRp 和 ORF8 区域的关键病毒蛋白在这 3 个月内通过人与人之间的传播发生了严重突变。我们还讨论了 SARS-CoV-2 快速突变的可能原因。
